No Data
Earnings Update: 10x Genomics, Inc. (NASDAQ:TXG) Just Reported And Analysts Are Trimming Their Forecasts
Barclays Maintains 10x Genomics(TXG.US) With Buy Rating, Cuts Target Price to $19
Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500
Morgan Stanley Maintains 10x Genomics(TXG.US) With Buy Rating, Maintains Target Price $30
A Quick Look at Today's Ratings for 10x Genomics(TXG.US), With a Forecast Between $14 to $30
TechBio Startup Cure51 Selects 10x Genomics Visium HD for New Drug Discovery Initiative
No Data
No Data
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
. I personally value the quality of management a lot when investing. So the cheaper it gets, the more I'm willing to buy.
La Tortuga : Why. Tutes are buying. This is a long steady climb. I like seeing green in my portfolio.
123456FEDCBA La Tortuga : Where is the green? Only see huge red for the longest time.
bowzerWoo_ OP 123456FEDCBA : yes I bought 4 at 28$ I sold on that last big drop to under 15$....lameeee . no growth just drop drop drop. all it's been doing the last year is steadily dropping. no recovery!!! sell!!
Dennisyap : I have 30 I. My portfolio. Who is tutes?